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Establishment and Characterization
of a Functionally Competent Type 2
Conventional Dendritic Cell Line
Matteo Pigni, Devika Ashok, Mathias Stevanin and Hans Acha-Orbea*
Department of Biochemistry CIIL, University of Lausanne, Épalinges, Switzerland
Dendritic cells (DCs) are the most potent antigen presenting cells and possess an
incomparable ability to activate and instruct T cells, which makes them one of the
cornerstones in the regulation of the cross-talk between innate and adaptive immunity.
Therefore, a deep understanding of DC biology lays the foundations to describe and to
harness the mechanisms that regulate the development of the adaptive response, with
clear implications in a vast array of fields such as the study of autoimmune diseases
and the development of new vaccines. However, the great difficulty to obtain large
quantities of viable non-activated DCs for experimentation have considerably hindered
the progress of DC research. Several strategies have been proposed to overcome
these limitations by promoting an increase of DC abundance in vivo, by inducing DC
development from DC progenitors in vitro and by generating stable DC lines. In the
past years, we have described a method to derive immortalized stable DC lines, named
MutuDCs, from the spleens of Mushi1 mice, a transgenic mouse strain that express
the simian virus 40 Large T-oncogene in the DCs. The comparison of these DC lines
with the vast variety of DC subsets described in vivo has shown that all the MutuDC
lines that we have generated so far have phenotypic and functional features of type 1
conventional DCs (cDC1s). With the purpose of deriving DC lines with characteristics of
type 2 conventional DCs (cDC2s), we bred a new Batf3−/− Mushi1 murine line in which
the development of the cDC1 subset is severely defective. The new MutuDC line that we
generated from Batf3−/− Mushi1 mice was phenotypically and functionally characterized
in this work. Our results demonstrated that all the tested characteristics of this new cell
line, including the expression of subset-determining transcription factors, the profile of
cytokine production and the ability to present antigens, are comparable with the features
of splenic CD4− cDC2s. Therefore, we concluded that our new cell line, that we named
CD4− MutuDC2 line, represents a valuable model for the CD4− cDC2 subset.
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INTRODUCTION
Dendritic cells (DCs) are a heterogeneous lineage of innate immune cells with a unique and
essential role in the initiation and orchestration of the adaptive immune response (1). Upon
encounter with pathogens, DCs become activated and undergo a series of functional modifications
that include induction of cytokine and chemokine production, regulation of surface marker
expression and increase of antigen presentation efficiency (2).
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Pathogen sensing by DCs is achieved by means of a broad
group of surface receptors called pattern recognition receptors
(PRRs). PRRs recognize specific molecular motifs, collectively
known as microbe associated molecular patterns (MAMPs),
which are conserved among pathogenic and non-pathogenic
microorganisms (3, 4). One of the most studied groups of PRRs
is the toll like receptor (TLR) family which in mouse comprises
twelve members, namely TLR1-9 and TLR11-13 (4). To carry out
their function, TLRs form binary protein complexes that can be
either homodimeric or heterodimeric, as in the case of TLR1/2
and TLR2/6, (5, 6), and that recognize MAMPs with distinct
ligand specificity. The recognition of a MAMP by its specific
TLR dimer triggers a signaling cascade that culminates in the
activation of DCs with consequent increase of surface markers,
like MHC-II and co-stimulatory molecules, and regulation of
several effector genes, including pro-inflammatory cytokines and
chemokines (7, 8).
DCs constantly endocytose self and foreign antigens, but
it is especially following activation and maturation that they
become highly efficient at forming peptide-MHC complexes for
antigen presentation to T cells (9). Endogenous self-antigens or
intracellular pathogen-derived antigens are presented to CD8+
T cells through direct MHC-I presentation. Instead, exogenous
antigens, endocytosed from the extracellular environment, can
be presented either to CD4+ T cells, by means of peptide-
MHC-II complexes, or to CD8+ T cells via the alternative
MHC-I pathway known as cross-presentation (9–11). Together
with antigen presentation through peptide-MHC complexes, the
upregulation of co-stimulatory molecules and the induction of
cytokine production that follow DC activation provide the three
canonical signals required for T cell activation (2).
As previously mentioned, DCs are very heterogeneous and
can be classified into several distinct subsets. At the steady
state, DCs are roughly divided into non-lymphoid tissue DCs,
which during inflammation circulate loaded with antigens from
the peripheral tissues to the draining lymph nodes through
the lymphatics (12, 13), and lymphoid tissue-resident DCs,
which differentiate and dwell in the lymphoid organs (14, 15).
Additionally, under inflammatory conditions, blood circulating
monocytes can differentiate into a subset of DCs known as
monocyte-derived/inflammatory DCs (moDCs) (12, 16–20). The
steady-state DC population is composed of two main subsets:
plasmacytoid DCs (pDCs), which are known to be major
producers of IFNα during antiviral response (21, 22), and
conventional DCs (cDCs) (23). CDCs are subdivided into type
1 cDCs (cDC1s) and type 2 cDCs (cDC2s) on the basis of
their ontogeny (24). In particular, the cDC1 subset includes
all the cDCs whose development depends on the basic leucine
zipper ATF-like transcription factor 3 (Batf3) (25, 26) and on
the interferon regulatory factor 8 (IRF8) (25, 27, 28), while
the cDC2 subset comprises all the cDCs that are independent
of these transcription factors and that, by contrast, develop
in an interferon regulatory factor 4 (IRF4)-dependent manner
(29–31). Notably, this ontogeny-based classification system
can be extended to cDCs across separate organs and species
(32), overcoming the confusion generated by the phenotypic
variability of analogous cDC subsets in different tissues. The
different DC subsets express a wide variety of subset- and tissue-
specific surface markers (1, 32) among which CD8α, CD11b, and
CD4 have been traditionally used in mouse to discriminate the
splenic resident cDC1s (spl-cDC1s) and cDC2s (spl-cDC2s) (33).
This varied assortment of DC subsets reflects a diversified
array of functional specificities in terms of pathogen sensing,
cytokine production and antigen presentation (34, 35). For
instance, cDC1s are characterized by high levels of TLR3 and
TLR9 but display selective lack of TLR7, while cDC2s have a
wider TLR profile but show limited or absent TLR3 expression
(36). Upon activation, cDC1s produce considerable quantities
of IL-12, while cDC2s are known to be poor producers of this
cytokine (33, 37, 38). Additionally, cDC1s are specialized in
MHC-I-mediated cross-presentation of extracellular antigens,
and hence they are more addressed toward cytotoxic T
lymphocyte priming, while cDC2s are mainly oriented to MHC-
II-mediated presentation and helper T cell activation (39–41).
In the past years, our group has developed a new method
to generate immortalized DC lines from the spleen of a murine
model of multisystem histiocytosis named Mushi1 (multisystem
histiocytosis line 1) (42). Mushi1 mice carry a transgenic
construct that contains the simian virus 40 Large T-oncogene
(SV40LgT) and an IRES-linked EGFP reporter under the control
of the 5.7 kb CD11c proximal promoter that restricts the
transgene expression almost exclusively to DCs (42, 43). Between
3 and 5 months of age, Mushi1 mice develop splenic tumors
caused by tumorigenic transformation of spl-cDC1s (42). From
the tumors, stable cell lines named MutuDCs (murine tumor
DCs) can be derived (44). These cells can be easily cultured
through standard procedures without additional growth factors
and are stable in long term culture for a minimum of 40 passages.
Meticulous analysis of MutuDCs has clearly demonstrated that
they share with spl-cDC1s all themain phenotypic and functional
characteristics including the cross-presentation ability, and hence
we refer to them as MutuDC1s (44).
In this work, we describe the derivation of the new CD4−
MutuDC2 line from splenic tumors of Batf3−/− Mushi1 mice
and we illustrate how the selective absence of cDC1s in this
genetic background (26) allowed to obtain a cell line whose
features are different from spl-cDC1s. We also show and discuss
the characterization of these cells demonstrating that their
phenotype and function are consistent with their belonging to the
CD4− spl-cDC2 subset.
MATERIALS AND METHODS
Mice
C57BL/6JOlaHsd mice were purchased from Harlan
Laboratories. Mushi1 (42), OT-I, and OT-II transgenic mice
were maintained and bred in our own facility. Batf3−/− mice in
a C57BL/6J background (26) were provided by Prof. Kenneth
M. Murphy (Washington University School of Medicine in
St. Louis, St. Louis, MO). All the animals were housed and
bred under specific pathogen free conditions and used at an
age of at least 8 weeks. Genomic DNA from pups of Batf3−/−
x Mushi1 litters was extracted by incubation of ear samples
at 95◦C in 600 µL of 50mM NaOH for 30min followed by
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addition of 50 µL of 1M Tris-HCl pH 8. The genomic DNA
was used for genotypic screening by PCR using the following
primers: pCD11c (5′-GGCAGCTGTCTCCAAGTTGCTCAG-
3′) and RβGR1 (5′-GGGTCCATGGTGATACAAGGG-3′) (42).
All animal experiments were performed after approval by
the cantonal veterinary office (Service de la consommation
et des affaires vétérinaires, Département du territoire et de
l’environnement, Permission no. VD2490.1).
Culture Conditions and Generation of
MutuDC Lines
Cells were kept in culture at 37◦C in a humidified incubator
with 5% CO2. Complete culture medium was composed as
follows: IMDM+GlutaMAXTM Supplement (31980, GIBCO),
10mM HEPES (15630, GIBCO), 0.075% NaHCO3 (from
7.5% NaHCO3 stock solution, 25080, GIBCO), 50µM β-
mercaptoethanol (31350, GIBCO), 8% heat inactivated FCS
(tested for toxicity toward DC cultures), 50 U/mL penicillin,
50µg/mL streptomycin (15070, GIBCO). Cells were harvested by
treatment with a non-enzymatic cell dissociation buffer (5mM
EDTA, 20mM HEPES in PBS). The derivation of the new CD4−
MutuDC2s was carried out as previously described for other
MutuDCs (44, 45). Spleens from diseased Batf3−/− Mushi1 were
cut with a scalpel and filtered through a 40µm cell strainer to
obtain single cell suspensions. The splenocytes were seeded in
serial two-fold dilution in a 24-well plate at a starting density
≥107 cells/well. After 8–16 h, non-adherent cells were removed
by washing the wells. The adherent cells were maintained in
24-well plates for 5–10 passages during which the wells were
frequently washed to remove non-adherent/dead cells or debris,
and culture medium was changed periodically. In the earliest
passages the cells were always kept at high density and split at
a maximum 1:2 dilution. When the cells became able to tolerate
1:6 splitting, the cultures were progressively expanded. The
MutuDCs chosen for the characterization described in this work
have been numbered 20956A (clone A frommouse HAO-20956).
Light Microscopy
Pictures of cells were obtained by photographing the
cultures directly with the EVOSTM FL Color Imaging System
(AMEFC4300, ThermoFisher SCIENTIFIC).
Splenocyte Isolation, Staining, and
Antibodies for Flow Cytometry
Spleens were cut into small pieces with a scalpel and incubated
for 20min at 25◦C in a freshly prepared collagenase D/DNase
I solution composed as follows: RPMI 1640+GlutaMAXTM
Supplement (61870, GIBCO), 2% FCS, 1 mg/mL collagenase
D (11088866001, ROCHE), 40µg/mL DNase I (10104159001,
ROCHE). After the digestion, the spleens were filtered through
a 40µm cell strainer to obtain single cell suspensions. All
the washing steps and acquisitions were carried out in FACS
buffer (3% Fetal Bovine Serum, 5mM EDTA in PBS). For
the staining, the cells were incubated for 30min on ice
with a staining mix composed of the appropriate antibody
combinations diluted in a 1:2 solution of FACS buffer and
supernatant from hybridoma 2.4G2. The cells were analyzed
immediately after staining or fixed in 1% paraformaldehyde
at room temperature for 10min, stored at 4◦C and analyzed
within 3 days after the staining. For intracellular staining the
eBioscienceTM Foxp3 / Transcription Factor Staining Buffer Set
(00-5523-00, ThermoFisher SCIENTIFIC) was used according to
manufacturer’s instructions. Flow cytometric data were acquired
with BD LSR-II or BD LSRFortessa cytometers (BD Biosciences)
and analyzed with FlowJo (version 10.0.8r1, Tree Star, Inc.).
The fluorochrome-conjugated monoclonal antibodies that were
used were specific for: B220 (CD45R) (clone RA3-6B2, Alexa
Fluor 700, eFluor 450, PE, PE-Cy7, eBioscience), CD4 (clone
RM4-5, APC, Pacific Blue, PE-Cy7, BioLegend, or APC, eFluor
450, PE-Cy7, PerCP-Cy5.5, eBioscience), CD8α (clone 53-6.7,
PE-Cy7, BD Biosciences, or APC, APC-eFluor 780, eFluor 450,
PE-Cy7, PerCP-Cy5.5, eBioscience), CD11b (clone M1/70, APC,
PE, BioLegend, or APC, APC-eFluor 780, eBioscience), CD11c
(clone N418, APC, PacificBlue, PE-Cy7, BioLegend, or eFluor
450, PE, PE-Cy7 eBioscience), CD24 (clone M1/69, APC, BD
Biosciences, or eFluor 450, eBioscience), CD40 (clone 1C10,
APC, PE, eBioscience), CD80 (clone 16-10A1, Brilliant Violet
421, BioLegend, or APC, eBioscience), CD86 (clone GL1, Alexa
Fluor 700, BioLegend, or APC, eBioscience), CD64 (FcγRI)
(clone X54-5/7.1, PE, BioLegend), CD172a (clone P84, APC, PE,
BD Biosciences), CD205 (clone NLDC-145, APC, BioLegend, or
clone 205yekta, PerCP-eFluor 710, eBioscience), CD206 (MMR)
(clone C068C2, PE, BioLegend), CLEC9A (CD370) (clone 7H11,
APC, PE, BioLegend, or clone 42D2, PE, eBioscience), F4/80
(clone BM8, APC, BioLegend, or eFluor 450, eBioscience),
FcεRIα (clone MAR-1, PE, BioLegend), FLT3 (CD135) (clone
A2F10, PE, eBioscience), Gr-1 (clone RB6-8C5, APC, BioLegend,
or PE, eBioscience), IFNγ (clone XMG1.2, PE, BD Biosciences,
or PE, BioLegend, or PE, PE-Cy7, eBioscience), IRF4 (clone
3E4, PE-Cy7, eBioscience), IRF8 (clone V3GYWCH, APC,
eBioscience), MHC-II (clone M5/114.15.2, PerCP, BioLegend,
or Alexa Fluor 700, PE, eBioscience), PDCA-1 (CD317) (clone
eBio129c, PE, eBioscience), TLR5 (clone ACT5, Alexa Fluor 647,
BioLegend).
TLR Stimulation and Cytokine Detection
CD4− MutuDC2s and MutuDC1s were seeded at a density of
2.5 × 105 cells/cm2 in 96-well or 48-well plates and incubated
for 24 h with 450 µL/cm2 of the following TLR agonists
diluted in complete medium: Pam3CSK4 (150 ng/mL, tlrl-pms,
InvivoGen), poly(I:C) (8.5µg/mL, tlrl-pic, InvivoGen), LPS
from E. coli (100 ng/mL, tlrl-peklps, InvivoGen), ultrapure
flagellin from B. subtilis (100 ng/mL, tlrl-pbsfla, InvivoGen),
FSL-1 (100 ng/mL, tlrl-fsl, InvivoGen), GardiquimodTM
(1µg/mL, tlrl-gdqs, InvivoGen), CpG ODN 1826 (1µM,
TriLink BIOTECHNOLOGIES). In all the experiments each
condition was plated in technical triplicate. The supernatants
were analyzed by ELISA for the presence of IL-6, IL-10, IL-12/IL-
23 p40, IL-12p70, and MCP-1(CCL2) using the following kits
according to manufacturer’s instructions: Mouse IL-6 ELISA Set
(555240, BD Biosciences) or Mouse IL-6 ELISA Ready-SET-Go!
(88-7064, eBioscience), Mouse IL-10 ELISA Set (555252, BD
Biosciences) or Mouse IL-10 (Interleukin-10) ELISA Ready-
SET-Go! (88-7104, eBioscience), Mouse IL-12 (p40) ELISA Set
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(555165, BD Biosciences), Mouse IL-12 (p70) ELISA Set (555256,
BD Biosciences), Mouse CCL2 (MCP-1) ELISA Ready-SET-Go!
(88-7391, eBioscience).
RNA Extraction, cDNA Synthesis, and
RT-qPCR
Total RNA from CD4− MutuDC2s and MutuDC1s was
extracted with the RNeasy Plus Mini Kit (74134, QIAGEN)
according to manufacturer’s instructions and stored in RNA
secure (AM7005, Thermo Fisher SCIENTIFIC). The synthesis
of cDNA was carried out using random nonamers and the
M-MLV reverse transcriptase kit (M1701, Promega) or the
SuperScriptTM Reverse Transcriptase kit (18064014, Thermo
Fisher SCIENTIFIC) according to manufacturer’s instructions,
with the addition of RiboLock RNase Inhibitor (EO0381,
Thermo Fisher SCIENTIFIC). DNA/RNA hybrids were removed
with RNase H (70054Y, Thermo Fisher SCIENTIFIC). cDNAs
were purified using the QIAquick PCR Purification Kit
(28104, QIAGEN). RNA and cDNA yields were quantified by
Nanodrop spectrophotometry (Thermo Fisher SCIENTIFIC).
RT-qPCR was carried out using KAPA SYBR R© FAST qPCR
kit for LightCycler R©480 (KK4611, SIGMA-ALDRICH) on a
LightCycler R©480 (384-well plate, 5 µL reaction) from Roche
Diagnostics. The following primers were used at the final
concentration of 500 nM: TLR3 FW (5′-GCGTTGCGAAGTG
AAGAA-3′), TLR3 REV (5′-TCGAGCTGGGTGAGATTT-3′),
TLR5 FW (5′-CCTCATCTCACTGCATACC-3′), TLR5 REV (5′-
TATTACCAACACGGGGCT-3′), ACTB FW (5′-CTGAACCC
TAAGGCCAACCGTG-3′), ACTB REV (5′-GGCATACAGGG
ACAGCACAGCC-3′). Every sample was analyzed in technical
triplicates.
T Cell Activation Assays
Ovalbumin-specific CD8+ and CD4+ T cells were isolated from
spleens and lymph nodes (brachial, inguinal and mesenteric)
of OT-I and OT-II mice, respectively, and purified using the
following MACS or EasySepTM kits: CD4+ T Cell Isolation
Kit, mouse (130-104-454, Miltenyi Biotec), CD8a+ T Cell
Isolation Kit, mouse (130-104-07, Miltenyi Biotec), EasySepTM
Mouse CD4+ T Cell Isolation Kit (19852, STEMCELLTM
TECHNOLOGIES), EasySepTM Mouse CD8+ T Cell Isolation
Kit (19853, STEMCELLTM TECHNOLOGIES). The T cell
isolation kits were used following manufacturer’s protocols
except for the buffers that were prepared as follows: MACS
buffer (0.5% FCS, 2mM EDTA in PBS), EasySep buffer (2% FCS,
1mM EDTA in PBS). A fraction of the purified T cells was
stained with fluorochrome-conjugated monoclonal antibodies
specific for TCR β chain (clone H57-597, Brilliant Violet 510,
BioLegend) and for either CD4 (clone RM4-5, APC, BioLegend
or eBioscience) or CD8α (clone 53-6.7, APC, eBioscience) and
analyzed by flow cytometry to assess T cell purity. The purified
T cells were stained with the cell proliferation dye eFluorTM 670
(65-0840, eBioscience) or eFluorTM 450 (65-0842, eBioscience).
CD4− MutuDC2s and MutuDC1s were plated in 96-well round
bottom plates at a density of 104 cells/well and incubated for 6–
8 h with the ovalbumin-derived peptides OVA332−339 (Protein
and Peptide Chemistry Facility, UNIL) or OVA257−264 (Protein
and Peptide Chemistry Facility, UNIL) or with the full-length
ovalbumin (vac-pova, InvivoGen) in the presence of CpG ODN
1826 (1µM, TriLink BIOTECHNOLOGIES). At the end of the
incubation, the supernatants were removed and the wells were
washed gently with fresh complete medium. The proliferation
dye-labeled T cells were plated with the MutuDCs at a density
of 105 cells/well. After 3 days (CD8+ T cells) or 4 days (CD4+
T cells) of co-culture, the supernatant was removed from each
well and the cells were restimulated for 6 h with phorbol
12-myristate 13-acetate (PMA) (10 ng/mL, P8139, SIGMA-
ALDRICH), ionomycin (500 ng/mL, I0634, SIGMA-ALDRICH)
in the presence of brefeldin A (00-4506-51, eBioscience). The
T cells were stained with fluorochrome-conjugated monoclonal
antibodies and analyzed by flow cytometry for proliferation and
IFNγ production.
Statistical Analyses
All the statistical analyses were carried out using GraphPad Prism
7.04.
RESULTS
Generation of Batf3−/− Mushi1 Mice and
Derivation of CD4− MutuDC2s
In the Mushi1 mouse, the development of splenic tumors is
invariably caused by spl-cDC1 transformation (42). In this study,
we aimed to design a strategy to favor the transformation
of spl-cDC2s over spl-cDC1s with the purpose of generating
new spl-cDC2-like MutuDC lines. To do this, we crossed
Mushi1 mice with Batf3−/− mice (Figure 1A) to introduce the
CD11c:SV40LgT transgenic construct in the Batf3−/− genetic
background where all the cDC1s are selectively absent (26, 46).
Batf3−/− Muhi1 mice started showing signs of histiocytosis
between 6 and 8 months of age (Figure 1B), with a delay
of around 3 months if compared with Mushi1 mice (42).
Similarly to sick Mushi1 mice, diseased Batf3−/− Mushi1
mice developed splenic tumors characterized by splenomegaly
(Figure 1C). Additionally, in Batf3−/− Mushi1 mice the
progression of the disease was occasionally associated with
peripheral lymphadenopathy (Figure 1D) that instead was never
observed in Muhi1 mice.
Cell line derivation from Batf3−/−Mushi1 splenic tumors was
carried out as previously described (44, 45) and is schematized
in Figure 2A. This procedure allowed to generate numerous
immortalized cell lines from several mice. After a first exploratory
phenotypic analysis, the most promising cell line, that in this
work is named CD4− MutuDC2 line, was chosen for further
phenotypic and functional characterization. At the steady state,
the stable CD4− MutuDC2s have round morphology with few
or absent dendritic processes (Figure 2B). They are adherent and
have a slight tendency to cluster (Figure 2B). In conditions of
prolonged culture, the CD4− MutuDC2s can be split at densities
as low as 1.5 × 104 cells/cm2 and maintain their phenotype
and function for at least 40 passages. With the increment of
passage number, moderate increase of clustering tendency and
slight reduction of adherence can be observed.
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FIGURE 1 | Batf3−/− Mushi1 mice develop splenic tumors with occasional
peripheral lymphadenopathy. (A) Breeding strategy to generate the new
Batf3−/− Mushi1 mouse strain. Mushi1 mice are heterozygous for a
transgenic construct which contains the SV40 Large T-oncogene under the
control of the murine CD11c promoter. Batf3−/− mice (B−/−) were crossed
with Mushi1 mice (M). Batf3+/− Mushi1 mice (B+/− M) from the offspring
were then backcrossed with B−/− mice. Starting from the second generation,
the strain was maintained by breeding B−/− M with B−/− mice. (B)
Age-dependent cumulative percentage of diseased Batf3−/− Mushi1 mice.
(C,D) Compared with healthy Batf3−/− Mushi1 controls (left), diseased mice
(right) show (C) spleen enlargement (D) and occasionally develop peripheral
lymphadenopathy.
When analyzed by flow cytometry, the CD4−MutuDC2s were
found to be homogeneous (Figures 2C,D) and to express the
SV40LgT-associated reporter EGFP even if at lower levels than
the previously derived MutuDC1s (Figure 2D). This observation
indicates lower expression of SV40LgT in the CD4− MutuDC2s
than in the MutuDC1s. In Mushi mice, higher levels of SV40LgT
correspond to earlier onset of histiocytosis suggesting a dose-
dependency of SV40LgT (42). Therefore, the lower expression
of SV40LgT observed in the CD4− MutuDC2s might explain
the delayed development of splenic tumors in Batf3−/− Mushi1
mice.
CD4− MutuDC2s Are Phenotypically
Similar to CD4− spl-cDC2s
To assess the phenotypic resemblance of the CD4−MutuDC2s to
spl-cDCs, we analyzed their expression of numerous extracellular
and intracellular markers in comparison to fresh spl-cDCs. To do
this, splenocytes from C57BL/6 mice were isolated, stained with
fluorochrome-conjugated monoclonal antibodies and compared
by flow cytometry with equally stained CD4− MutuDC2s
(Figures 3A–E). Spl-cDCs were defined as CD11chiMHC-IIhi
cells, and within this population, spl-cDC1s and spl-DC2s were
distinguished on the basis of either CD8α or CD11b expression
(Figure 3A). We observed that, similarly to fresh spl-cDCs,
the CD4− MutuDC2s are CD11chiMHC-IIhiF4/80lo/−B220−Gr-
1−PDCA-1− (Figure 3B). At the steady state, the expression of
the co-stimulatory molecules CD80 and CD86 was found to be
higher than in spl-cDCs in which the levels of these markers were
low but detectable (Figure 3B). By contrast, CD40 expression,
that was low in spl-cDCs, was not detectable in the CD4−
MutuDC2s (Figure 3B).
As mentioned, IRF8 and IRF4 have a primary role in the
development of cDC1s and cDC2s, respectively (24). Fully
differentiated cDC1s and cDC2s maintain a divergent expression
of these two transcription factors. Indeed, spl-cDC1s express high
levels of IRF8 and display low IRF4 expression, while, by contrast,
both the CD4+ and the CD4− spl-cDC2s have low levels of
IRF8 and higher expression of IRF4 (31, 42), even though IRF4
deficiency affects more severely the development of the former
subset (31). In order to correctly determine the belonging of the
CD4− MutuDC2s to either the spl-cDC1 or the spl-cDC2 subset,
we analyzed them for the expression of IRF4 and IRF8. Our
results showed that the CD4− MutuDC2s express high levels of
IRF4 and low levels of IRF8, with a profile that mirrors almost
perfectly the pattern observed in spl-cDC2s as opposed to spl-
cDC1s (Figure 3C). Consequently, we concluded that the CD4−
MutuDC2s belong to the spl-cDC2 subset.
To further prove the phenotypic similarity of the CD4−
MutuDC2s to spl-cDC2s we analyzed them for the expression
of several spl-cDC subset-characterizing markers in comparison
with fresh spl-cDC1s and spl-cDC2s. The spl-cDC2-specific
markers CD11b and CD172a (47–50) appeared to be strongly
expressed in the CD4− MutuDC2s at an even higher level
than in spl-cDC2s, while CD4 expression was found to be
absent comparably to the CD4− subpopulation of spl-cDC2
(Figure 3D). Analysis of the spl-cDC1-specific markers CD8α,
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FIGURE 2 | CD4− MutuDC2s are derived from Batf3−/− Mushi1 splenic tumors. (A) Schematic representation of CD4− MutuDC2-derivation procedure. Splenocytes
from Batf3−/− Mushi1 (B−/− M) splenic tumors were isolated and seeded in serial two-fold dilutions in 24-well plates. The adherent cells were maintained in 24-well
plates for 5–10 passages until they became accustomed to culture conditions. The cultures were progressively expanded into plates and flasks with larger growth
surfaces and frozen or used for experiments. (B) Light microscopy image of CD4− MutuDC2s. (C) Flow cytometric analysis and gating of CD4− MutuDC2s. (D) Flow
cytometric comparison of expression of the SV40LgT-associated reporter EGFP in CD4− MutuDC2s and in MutuDC1s.
CLEC9A, CD205, and CD24 (40, 51–53) revealed that the
CD4− MutuDC2s are CD8α− and CLEC9A− but express CD205
and CD24 at higher levels than the spl-cDC2s (Figure 3D
and Supplementary Figure 2). However, consistently with a spl-
cDC2 phenotype, the expression of these two markers is lower in
the CD4− MutuDC2s than in the MutuDC1s (Figure 3F).
Since some characteristics of the CD4− MutuDC2s are
consistent with the hypothesis of their belonging to the moDC
subset, we analyzed them for the expression of moDC- or cDC-
distinguishing markers to exclude the possibility of a monocytic
origin. The two markers FcεRIα and CD64, which are considered
very specific for moDCs (20), are respectively negative and low in
the CD4−MutuDC2s, with expression profiles that are very close
to the ones observed in spl-cDCs (Figure 3E). CD206, known
as macrophage mannose receptor (MMR), is also considered
a moDC-characterizing marker even if its expression in cDC
subsets is debated (20, 54–57). Analysis of CD206 expression in
the CD4− MutuDC2s showed that they express CD206 at low
levels (Figure 3E) in line with a small cell population that is
present within the cDC gate (Figures 3A,E). One of the main
inducers of DC development is the the FMS-like tyrosine kinase
3 ligand (FLT3L) (58, 59). Therefore, its receptor FLT3 is one
of the most characteristic markers of DCs. Accordingly, when
analyzed by flow cytometry, spl-cDCs were found to be FLT3+
(Figure 3E). Surprisingly, the analysis of surface levels of FLT3
on the CD4− MutuDC2s showed no detectable expression of
this marker (Figures 3E,G). However, intracellular analysis of its
expression in the CD4− MutuDC2s revealed high intracellular
levels of FLT3 (Figure 3G).
CD4− MutuDC2s Are Weakly Activated by
poly(I:C) or Flagellin and Express Low
Levels of TLR3 but Have High Expression
of TLR5
The existence of several distinct DC subsets reflects a great variety
of differential functional specificities, including fundamental
aspects related to pathogen sensing and cytokine production
(34, 35). Spl-cDC1s are known to be the only spl-DC subset to
express TLR3 (36) and represent one of the primary producers of
IL-12p70 during inflammation. By contrast, spl-cDC2s lack TLR3
expression and are weak producers of IL-12p70 (33, 36–38), but
express IL-6, IL-23, and MCP-1(CCL2) (42, 60, 61). To assess the
TLR expression profile of the CD4− MutuDC2s and their ability
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FIGURE 3 | CD4− MutuDC2s share the surface and intracellular marker expression profile with CD4− spl-cDC2s. (A–E) Splenocytes from C57BL/6 mice were
isolated by digestion of spleens with collagenase D followed by filtration through a 40µm cell strainer. CD4− MutuDC2s, MutuDC1s and splenocytes were stained
with different antibody cocktails that always contained anti-MHC-II and anti-CD11c antibodies to distinguish spl-cDCs. Antibodies specific for either CD8α or CD11b
were included in every staining cocktail to identify spl-cDC1s and spl-DC2s. The cells were analyzed by flow cytometry. (A) Gating strategy to discriminate spl-cDCs
and their subsets. The dash-dotted lines show the fluorescence-minus-one (FMO) controls acquired for each marker. (B) CD4− MutuDC2s and spl-cDC subsets were
(Continued)
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FIGURE 3 | compared for the expression of the indicated surface markers. The gating strategies applied to analyze CD11c and MHC-II expression in the different
spl-cDC subsets are detailed in Supplementary Figure 1. The dash-dotted lines show the FMO controls acquired for each marker. (C) CD4− MutuDC2s and
spl-cDCs were compared for the expression of the spl-cDC subset-specific transcription factors IRF4 and IRF8. FMO controls: CD4− MutuDC2s (dash-dotted line),
spl-DC1s (dotted line), spl-DC2s (thin solid line). (D) CD4− MutuDC2s and spl-cDC subsets were compared for the expression of the indicated spl-cDC
subset-specific surface markers. The dash-dotted lines show the FMO controls acquired for each marker. (E) CD4− MutuDC2s and spl-cDC subsets were compared
for the expression of the indicated moDC or spl-cDC characterizing surface markers. The dash-dotted lines show the FMO controls acquired for each marker. (F)
CD4− MutuDC2s and MutuDC1s were compared for the expression of the indicated spl-cDC1-specific surface markers. The dash-dotted lines show the FMO
controls acquired for each marker. (G) Intracellular analysis of FLT3 expression in CD4− MutuDCs. The dash-dotted line shows the background fluorescence of
unstained cells. All the results are representative of two to six independent experiments.
to respond to TLR stimulation, we treated them with different
TLR ligands and measured their production of IL-6, IL-12/IL-
23 p40, IL-12p70, and MCP-1(CCL2) (Figure 4A and data not
shown). Additionally, considering the ability of some DC subsets
to produce the anti-inflammatory cytokine IL-10 in response
to TLR stimulation (62), we measured also IL-10 levels in the
supernatants of stimulated CD4− MutuDC2s. The majority of
the tested TLR ligands induced robust production of IL-6 and
MCP-1(CCL2). With a similar ligand-dependent pattern, modest
IL-12/IL-23 p40 secretion was observed, especially following
treatment with the TLR4 ligand LPS to which the MutuDC1s
respond weakly (44). However, after stimulation of the CD4−
MutuDC2s with the TLR3 ligand poly(I:C) or the TLR5 ligand
flagellin, we measured only low or undetectable production of
IL-6, IL-12/IL-23 p40, and MCP-1(CCL2) (Figure 4A). These
findings indicated a limited capacity of the cells to respond to
TLR3 and TLR5 stimulation. In addition, none of the tested TLR
ligands induced production of IL-12p70 and IL-10 at detectable
levels. By contrast, in the same conditions the MutuDC1s
responded mainly to TLR3 and TLR9 ligands by producing IL-
12/IL-23 p40, IL-12p70, IL-6, and IL-10, while they failed to
secrete detectable levels of MCP-1(CCL2) (data not shown).
We reasoned that a low expression of TLR3 and TLR5 could
explain the weak responsiveness of the CD4− MutuDC2s to
poly(I:C) and flagellin. To test this possibility, we measured by
RT-qPCR the levels of TLR3 and TLR5 mRNAs in the CD4−
MutuDC2s in comparison to the MutuDC1s which are known
to have high expression of TLR3 (44) and low levels of TLR5
(unpublished RNA-seq data-sets). In line with our hypothesis,
TLR3 expression was found to be around eight-fold lower
in the CD4− MutuDC2s than in the MutuDC1s (Figure 4B).
Surprisingly, the CD4− MutuDC2s showed five- to six-fold
higher expression of TLR5 than theMutuDC1s (Figure 4B). Flow
cytometric comparison of the CD4− MutuDC2s with fresh spl-
cDCs further confirmed this observation by showing that TLR5
levels are higher in the CD4− MutuDC2s than in spl-cDC2s
(Figure 4C).
CD4− MutuDC2s Are Capable of
MHC-I-Mediated and MHC-II-Mediated
Priming of CD8+ and CD4+ T Cells but Do
Not Cross-Present Antigens Through
MHC-I
Upon activation, DCs undergo a process of maturation which
entails several morphological and functional modifications
which contribute to the efficient priming of T cells, including
upregulation of co-stimulatory molecules, increase of surface
MHC and development of dendrites (2, 63). To test the ability
of our cell line to undergo such maturation, we activated
the CD4− MutuDC2s with CpG ODN and analyzed them by
flow cytometry. The activated CD4− MutuDC2s increased their
adherence and showed modified morphology characterized by
more tapered shape, enlarged size and presence of granules in
the cytoplasm (data not shown). The levels of MHC-II, CD80
and CD86, which are already high in resting CD4− MutuDC2s
(Figure 3B), were increased after stimulation with CpG ODN
(Figure 5A). Also CD40, which is not expressed by CD4−
MutuDC2s in the resting state (Figure 3B), was upregulated
under these conditions (Figure 5A).
To test the ability of the CD4− MutuDC2s to activate T
cells, we pulsed them, in the presence of CpG ODN, with
increasing concentrations of the ovalbumin (OVA)-derived
peptides OVA257−264 or OVA323−339, which are respectively
restricted to MHC-I and MHC-II. OVA-specific CD8+ or CD4+
T cells were isolated respectively from OT-I and OT-II mice,
stained with a proliferation dye and co-cultured with OVA
peptide-pulsed CD4− MutuDC2s. The percentage of activated
T cells, defined as proliferating IFNγ+ cells, was measured
by flow cytometry (Figure 5B). This analysis showed that,
in the presence of CD4− MutuDC2s pulsed with increasing
concentrations of MHC-I-restricted or MHC-II-restricted OVA
peptides, the percentage of activated CD8+ or, respectively,
CD4+ T cells increased accordingly (Figure 5C left, and
Supplementary Figure 3). These results demonstrate that the
CD4− MutuDC2s have retained the ability to induce MHC-I-
mediated and MHC-II-mediated T cell activation.
In an analogous experimental setup, we pulsed the CD4−
MutuDC2s with increasing concentrations of the full-length
OVA (OVAFL). When co-cultured with OVA-specific CD4
+
T cells, the OVAFL-pulsed CD4
− MutuDC2s induced T cell
activation in an antigen concentration-dependent manner
(Figure 5C bottom right and Supplementary Figure 3). Thus,
this result not only confirmed that the CD4− MutuDC2s have
retained the capacity to activate T cells, but also showed that
they are capable of endocytosing and processing extracellular
antigens for presentation on MHC-II. By contrast, when we
pulsed the CD4− MutuDC2s with increasing concentrations
of OVAFL and co-cultured them with OVA-specific CD8
+ T
cells, we did not observe T cell activation. Instead, in the
same conditions the MutuDC1s were able to induce CD8+
T cells to proliferate and produce IFNγ (Figure 5C top right
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FIGURE 4 | CD4− MutuDC2s respond weakly to TLR3 and TLR5 ligands and
have low TLR3 expression but high levels of TLR5. (A) CD4− MutuDC2s were
stimulated with specific TLR ligands: TLR1/2 ligand Pam3CSK4, TLR3 ligand
poly(I:C), TLR4 ligand LPS, TLR5 ligand flagellin, TLR2/6 ligand FSL-1, TLR7
ligand Gardiquimod, TLR9 ligand CpG ODN. After 24 h, the supernatants were
collected and analyzed by ELISA to determine the concentration of IL-6,
IL-12/IL-23 p40, and MCP-1(CCL2). The graphs show the results of five
independent experiments represented as box-and-whiskers plots: mean (+),
median (horizontal line), interquartile range (box), min/max values (whiskers). To
assess significance, every tested condition was compared with the untreated
control by Kruskal-Wallis testing followed by uncorrected Dunn’s testing (*p <
0.05, **p < 0.01, ***p < 0.001, NS, not significant; ND, not detectable). For
the statistical analysis, all the measures below the lower detection limit of the
assay were replaced with the value of the detection limit. (B) Expression of
TLR3 and TLR5 was measured by RT-qPCR in CD4− MutuDC2s compared
with MutuDC1s. Fold expression in CD4− MutuDC2s relative to MutuDC1s
was calculated with the 2−11Ct method using β-actin expression as a
reference for normalization. Data are presented as mean and SD of the log2
fold expression values from two independent experiments. The results were
analyzed by two-tailed unpaired t-testing (*p < 0.05). (C) Flow cytometric
analysis of TLR5 expression in CD4− MutuDC2s compared with spl-cDC1s
and spl-cDC2s. The isolation of splenocytes and the staining were carried out
as described in Figure 3. The dash-dotted lines show the FMO controls not
stained with anti-TLR5 antibody. The results are representative of two
independent experiments.
and Supplementary Figure 3). These results showed that the
CD4− MutuDC2s are not capable of antigen cross-presentation
in contrast to the MutuDC1s which are known to share this
functional feature with their splenic counterpart (44).
FIGURE 5 | CD4− MutuDC2s upregulate co-stimulatory molecules upon
activation and display MHC-I-mediated and MHC-II-mediated activation of T
cells but fail to cross-present antigens through MHC-I. (A) CD4− MutuDC2s
were incubated with medium or with CpG ODN. After 20 h they were stained
with fluorescent-labeled antibodies specific for MHC-II, CD80, CD86, or CD40
and analyzed by flow cytometry. The graphs relative to untreated CD4−
MutuDC2s are the same shown in Figure 3B. (B,C) CD4− MutuDC2s or
MutuDC1s were pulsed, in the presence of CpG ODN, with full length
ovalbumin (OVAFL ) or with the MHC-I-restricted peptide OVA257−264 or with
the MHC-II-restricted peptide OVA323−339 at the indicated concentrations.
OVA-specific CD8+ or CD4+ T cells were isolated respectively from OT-I and
OT-II mice and labeled with a proliferation dye. In the MHC-I T cell activation
assay (C, top left), the CD8+ T cells were co-cultured for 3 days with
OVA257−264-pulsed CD4
− MutuDC2s. In the MHC-I antigen
cross-presentation assay (C, top right), the CD8+ T cells were co-cultured for
3 days with either OVAFL-pulsed CD4
− MutuDC2s or OVAFL-pulsed
MutuDC1s. In the MHC-II T cell activation assay (C, bottom), the CD4+ T cells
were co-cultured for 4 days with either OVA323−339-pulsed or OVAFL-pulsed
CD4− MutuDC2s. At the end of the co-cultures, the T cells were restimulated
with PMA and ionomycin in the presence of brefeldin A and prepared for flow
(Continued)
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FIGURE 5 | cytometric analysis by staining them with fluorescent-labeled
antibodies specific for IFNγ and either CD4 or CD8α. (B) Gating strategy. The
gate P1 contains the activated T cells defined as proliferating IFNγ+ cells. (C)
The percentage of T cells in the gate P1 measured in each tested condition
was plotted against the respective antigen concentration. The results are
presented as mean and SD of technical triplicates and are representative of
two to three independent experiments.
DISCUSSION
DCs are well known for their scarcity in vivo that limits
tremendously their accessibility for experimentation (64, 65). In
addition, isolated DCs are very sensitive to long term culture
and under these conditions they easily undergo functional
modification, spontaneous activation and cell death (66, 67).
For these reasons, significant efforts have been made to create
suitable and reliable models for the study of DC biology. Several
procedures have been proposed to simplify the access to sufficient
amounts of viable and non-activated DCs for experimentation
by differentiating DC progenitors in vitro and by expanding the
number of DCs in vivo (68). However, despite their indisputable
value, these methods still display disadvantages including the
need for additional steps of cell isolation and purification,
as well as the sensitivity, the functional instability and the
limited lifespan in long term culture of the cells that they
generate. Therefore, a widely pursued alternative to the in vitro-
differentiation and in vivo-expansion strategies is represented
by stable DC lines. Several approaches have allowed to generate
stable DC lines (68) which in most cases have demonstrated to
be very good models to study single aspects of DC biology (69–
74). However, specific functional features of different DC subsets
are often found concomitantly in several DC lines, raising doubts
about their ability to maintain and fully represent the DC-subset
functional specificities observed in vivo (75–83). Moreover, the
need for special culture conditions, like growth at low permissive
temperature (77, 83) or constant supplementation with growth
factors (78, 84, 85), possibly represents an additional technical
complication for the maintenance of some DC lines in long-term
culture. Additionally, a relevant and yet often neglected caution
is required when the capacity of the DC lines to maintain fully
unaltered their phenotypic and functional properties over the
passages, and especially at high passage number, has not been
extensively ascertained.
Among the different examples of oncogene-based approaches
to immortalize DC lines, several strategies are based on ex
vivo transduction or transfection of DCs with the SV40LgT
(77, 83, 86). Our approach is different because it is based on the
generation of SV40LgT-transgenic mice and on the transgene-
induced transformation of DCs in vivo with consequent
development of DC tumors (42). Our group generated
several SV40LgT-transgenic murine lines where the transgene
expression was restricted to DCs (42). Among them we selected
the one, the Mushi1 line, in which the transgene expression was
sufficient to induce transformation of DCs and development
of DC tumors, but not high enough to cause functional
modifications of the cells. Finally, from the DC tumors we were
able to derive the stable immortalized MutuDC lines (44). In
parallel, we generated with a similar strategy several KO and
transgenic MutuDC lines by crossbreeding the parental KO
or transgenic murine lines with Mushi1 mice (44, 45). This
crossbreeding approach can be applied to introduce virtually
any kind of mutation in the cell lines or to derive them
from any different genetic background. Thus, this strategy
confers great versatility to our method and represents one of
its main advantages. Additionally, the recent development and
diffusion of genome-editing methods has enormously increased
the possibilities to modify our cell lines in vitro (44, 45).
All the MutuDC lines generated so far from Mushi1 mice
derive from spl-cDC1s (44), and therefore they are named
MutuDC1s. To obtain new MutuDC lines with phenotype
and functional properties of spl-cDC2s, we applied the
crossbreeding strategy to Batf3−/− mice which are devoid
of spl-cDC1s (26, 46). As expected, the Batf3−/− Mushi1
mice developed splenic tumors, even if with a delayed onset
of the disease if compared with Mushi1 mice (42). Given
the concentration-dependency of the SV40LgT (42), this
difference can be explained by our previous observation that
in Mushi1 mice the levels of the transgene expression are
lower in spl-cDC2s than in spl-cDC1s (42). Consequently,
the oncogenic transformation is likely to occur earlier in
spl-cDC1s than in spl-cDC2s, possibly explaining why all
the MutuDCs generated from Mushi1 mice derive from spl-
cDC1s.
From the splenic tumors of Batf3−/− Mushi1 mice, we
derived the new CD4− MutuDC2 line whose characterization
is described in this work. The expression of the SV40LgT was
measured in the CD4− MutuDC2s through the analysis of its
associated EGFP reporter. We found that the CD4− MutuDC2s
express lower levels of the transgene than the previously derived
MutuDC1s, reflecting the difference observed between spl-
cDC2s and spl-cDC1s in Mushi1 mice.
To assess the belonging of our CD4− MutuDC2s to one of
the spl-DC subsets, we analyzed their surface and intracellular
marker expression profile and compared them with freshly
isolated spl-DCs. The CD4− MutuDC2s display high levels of
CD11c and MHC-II with lack of the pDC-specific markers
B220, Gr-1 and PDCA-1. Additionally, in their resting state
they are CD80hi and CD86hi. These observations demonstrated
that the CD4− MutuDC2s have a relatively mature spl-cDC
phenotype. Analysis of expression of the subset-determining
transcription factors IRF4 and IRF8 showed that, comparably
to spl-cDC2s, the CD4− MutuDC2s express high IRF4 and low
IRF8. Therefore, we concluded that they belong to the spl-cDC2
subset. Additional surface marker analysis further corroborated
this conclusion by showing that the CD4− MutuDC2s strongly
express the spl-cDC2-distinctive markers CD11b and CD172a
and have low levels of CD4, comparably to the CD4− spl-cDC2
subset. The markers CD8α, CLEC9A, CD205, and CD24 are
known to be specifically expressed by spl-cDC1s (40, 51–53). In
our CD4− MutuDC2s, CD8α and CLEC9A are not expressed,
but the levels of CD205 and CD24 are higher than in fresh
CD4− spl-cDC2s. However, the comparison between the CD4−
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MutuDC2s and the MutuDC1s shows that the expression of
CD205 and CD24 is still lower in the former, in agreement
with the differences observed in vivo between spl-cDC2s and
spl-cDC1s. It should be mentioned that the levels of CD205
are also higher in the MutuDC1s if compared with freshly
isolated spl-cDC1s (44). This increase of CD205 expression
both in the CD4− MutuDC2s and in the MutuDC1s reminds
of what is observed in overnight cultures of ex vivo spl-
cDCs in the presence of GM-CSF, where CD205 expression is
upregulated both in spl-cDC2s and in spl-cDC1s but remains
higher in the latter (87). Concerning CD24 expression in the
CD4− MutuDC2s, we cannot fully explain the upregulation
of this marker. However, it has been shown that CD24int
and, to a lesser extent, CD24hi DC precursors maintain
the potential to generate spl-cDC2s (18). Moreover, several
examples of CD11b+CD24+ cDC2s, which share at least partially
developmental origin, phenotype and functional characteristics
with spl-cDC2s (23, 29, 32, 35), can be found among the mucosal
cDC populations in lung (29, 88), small intestine (32), and nose
(89).
Many of the phenotypic characteristics that we described
are consistent with a moDC phenotype. However, in Mushi1
mice, SV40LgT expression is driven by the 5.7 kb CD11c
proximal promoter which restricts the transgene expression to
DCs (43). Indeed, the SV40LgT-associated reporter, the IRES-
linked EGFP, is not detectable in CD11clo macrophages and
monocytes, demonstrating no expression of the transgene in
these cell types (unpublished results). This makes it highly
unlikely that the cell line here described is monocyte-derived.
Consistently, the analysis of the moDC-specific markers Ly-
6C (Gr-1), FcεRIα, and CD64 (20), which are negative or
low in the CD4− MutuDCs, highlights this conclusion. In
further agreement with the results discussed above, the CD4−
MutuDCs express high levels of the DC-defining marker FLT3,
in spite of an unusual intracellular localization. When we
generate DC lines, they become able to grow at low densities
only after several passages. We think that this is due to
the fact that, during the derivation process, we select for
cells that can secrete growth factors that favor DC growth.
Consistently, at low densities the cells preferentially grow in
conditioned medium. A likely growth factor is FLT3L whose
binding to its receptor FLT3 has been shown to induce the
dimerization and internalization of FLT3 (90). Therefore, the
presence of FLT3L in the culture medium would explain the
intracellular localization of FLT3 that we observe in the CD4−
MutuDC2s.
Distinct profiles of TLR and cytokine expression represent
an additional characterizing difference between splenic DC
subsets. For instance, spl-cDC1s are known to express mainly
TLR3 and TLR9 (36) and to be major producers of IL-
12p70 (37, 38). On the contrary, they do not produce the
chemokine MCP-1(CCL2) (42). The picture is reversed in
spl-cDC2s which express a broader array of TLRs, with the
well described exception of TLR3 (36), and produce MCP-
1(CCL2), IL-6, and IL-23 but only limitedly IL-12p70 (37,
38, 60, 61). Consistently, after stimulation with the ligands of
TLR1/2, TLR4, TLR2/6, TLR7, and TLR9, our CD4− MutuDC2s
responded by producing IL-6, MCP-1(CCL2), and IL-12/IL-
23 p40 but did not express detectable levels of IL-12p70.
Additionally, in line with the limited cytokine production
observed after stimulation with the TLR3 ligand poly(I:C),
transcription analysis showed very low levels of TLR3 mRNA.
We also observed that the CD4− MutuDC2s exhibit a generally
weak responsiveness to treatment with the TLR5 ligand flagellin,
in apparent contrast with their relatively high expression of
TLR5.
Several studies in the past have analyzed TLR5 expression
in different DC subsets. For example, intestinal lamina propria
CD11b+ cDC2s show high levels of TLR5 and rely considerably
on this receptor for detection of pathogens, maturation and
induction of cytokine production (70, 91, 92). By contrast, our
knowledge is less precise regarding spl-cDCs. Indeed, while
some studies have shown that TLR5 is expressed by spl-cDCs,
in particular by spl-cDC2s (36, 93), in other cases TLR5 was
found to be very low or absent (70, 91, 92, 94). Interestingly,
just one study could show in vitro a connection between TLR5
expression and direct flagellin-induced maturation of spl-cDCs
(93), while in other reports this effect was not observed (94, 95).
Additionally, even in the former case, flagellin always induced
a very limited or absent production of cytokines like IL-12 and
IL-6. These observations are consistent with a differential tissue-
and DC subset-specific role of TLR5. In agreement with this
hypothesis, TLR5 was shown to function also as an endocytic
receptor that mediates the uptake of flagellin promoting MHC-II
presentation of flagellin epitopes to CD4+ T cells (96). Further
investigation of this model showed that the CD4− spl-cDC2s
are the main subset among the spl-cDCs to carry out this
TLR5-mediated flagellin processing pathway (97). Our results
show very low, and yet detectable, levels of TLR5 in spl-
cDC2s as opposed to spl-cDC1s that are TLR5− (Figure 4C).
Instead, TLR5 expression is high in the CD4− MutuDC2 line.
However, the upregulation of TLR5 displayed by the CD4−
MutuDC2s, together with their low responsiveness to flagellin,
appears to integrate perfectly in the context of the functional
specialization of the CD4− spl-cDC2s, rather than representing
a divergence of the CD4− MutuDC2 line from its splenic
counterpart.
In addition to the induction of cytokine production,
the encounter of DCs with a pathogen initiates a process
of maturation that causes several functional modifications
including upregulation of the co-stimulatory molecules CD40,
CD80, and CD86, increase of the surface levels of MHC
molecules and reduction of the antigen-uptake capacity of DCs,
accompanied by an increase of their ability to process antigenic
peptides and load them into MHC complexes for presentation
to T cells (2, 7–9). All these elements are essential to ensure
the efficient priming of T cells and to initiate an appropriate
adaptive response. Upon treatment with CpG ODN, the CD4−
MutuDC2s upregulate CD40, CD80, and CD86 and increase
their surface levels of MHC-II. When pulsed, in the presence
of CpG ODN, with an ovalbumin-derived MHC-II-restricted
peptide or with the full-length ovalbumin, they are able to
take up the antigen and present it to antigen-specific CD4+
T cells. We speculate that the need of a rather high antigen
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concentration in our presentation assays could be linked to the
relatively mature phenotype that the CD4− MutuDC2s show
at the steady state, which might imply a reduced endocytic
capacity in favor of a higher antigen processing and presentation
efficiency. The CD4− MutuDC2s also proved to be very efficient
in the direct MHC-I-mediated activation of CD8+ T cells.
Therefore, their inability to cross-present antigens to CD8+ T
cells, even at the highest concentrations, mirrors precisely the
functional distinction that is observed in vivo between the cross-
presenting spl-cDC1s and the non-cross-presenting spl-cDC2s
and further distinguishes the CD4− MutuDC2s from moDCs
(19, 56, 98).
In conclusion, we have exploited the versatility of our
SV40LgT-based derivation method to generate the new CD4−
MutuDC2 line which has striking phenotypic and functional
resemblance to the CD4− spl-cDC2 subset. This cell line
has already proven to be a reliable model for the study of
cDC2s. Indeed, in a recent report from our group, resistance
to collagen induced arthritis (CIA) was partially recovered
by the adoptive transfer of CD4− MutuDC2s in a CIA-
susceptible CD11b−/− mouse model, highlighting a potential
tolerogenic role of cDC2s in the modulation of autoimmune
responses (99). Furthermore, the CD4− MutuDC2s have been
successfully transduced with a CRISPR-Cas9 editing system to
generate a new CD11b−/− CD4− MutuDC2 line (unpublished
data). As we have shown, the new CD4− MutuDC2s are
simple to culture and can be expanded at will, providing a
virtually unlimited source of cells for experimentation. They can
be easily manipulated with standard experimental techniques
and display great stability of their phenotypic and functional
properties in long term culture as long as their passage
number is maintained below 40-50. For these reasons the CD4−
MutuDC2s represent a new valuable tool for the study of
DC biology.
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